Search Results - "Dirk Waldschmidt"

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score by Scheiner, Bernhard, Pomej, Katharina, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Waidmann, Oliver, Himmelsbach, Vera, Schulze, Kornelius, von Felden, Johann, Fründt, Thorben W., Stadler, Marc, Heinzl, Harald, Shmanko, Kateryna, Spahn, Stephan, Radu, Pompilia, Siebenhüner, Alexander R., Mertens, Joachim C., Rahbari, Nuh N., Kütting, Fabian, Waldschmidt, Dirk-Thomas, Ebert, Matthias P., Teufel, Andreas, De Dosso, Sara, Pinato, David J., Pressiani, Tiziana, Meischl, Tobias, Balcar, Lorenz, Müller, Christian, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Personeni, Nicola, Rimassa, Lorenza, Bitzer, Michael, Trojan, Jörg, Weinmann, Arndt, Wege, Henning, Dufour, Jean-François, Peck-Radosavljevic, Markus, Vogel, Arndt, Pinter, Matthias

“…Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC)…”
Get full text

Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial by Zhang, Danmei, Benedikt Westphalen, C., Quante, Michael, Waldschmidt, Dirk T., Held, Swantje, Kütting, Fabian, Dorman, Klara, Heinrich, Kathrin, Weiss, Lena, Boukovala, Myrto, Haas, Michael, Boeck, Stefan, Heinemann, Volker, Probst, Victoria

“…The combination of gemcitabine/nab-paclitaxel is an established standard treatment in the first-line treatment of metastatic ductal adenocarcinoma of the…”
Get full text

Proposal for a definition of "Oligometastatic disease in pancreatic cancer" by Damanakis, Alexander I, Ostertag, Luisa, Waldschmidt, Dirk, Kütting, Fabian, Quaas, Alexander, Plum, Patrick, Bruns, Christiane J, Gebauer, Florian, Popp, Felix

“…To date, patients with metastasized pancreatic ductal adenocarcinoma (PDAC M1) are regarded as a uniform collective. We hypothesize the existence of…”
Get full text

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC) by Gebauer, Florian, Damanakis, Alexander Ioannis, Popp, Felix, Quaas, Alexander, Kütting, Fabian, Lutz, Katrin, Held, Swantje, Deuß, Burkhard, Göser, Tobias, Waldschmidt, Dirk, Bruns, Christiane

“…According to current guidelines, treatment of patients with hepatic oligometastasis in pancreatic cancer is not reflected and systemic chemotherapy is…”
Get full text

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study by Westphalen, C Benedikt, Kukiolka, Tobias, Garlipp, Benjamin, Hahn, Lars, Fuchs, Martin, Malfertheiner, Peter, Reiser, Marcel, Kütting, Fabian, Heinemann, Volker, Beringer, Andreas, Waldschmidt, Dirk T

“…Gemcitabine/erlotinib treatment offers limited benefit in unselected patients with pancreatic ductal adenocarcinoma (PDAC). Development of skin rash has been…”
Get full text

Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial by Fietkau, Rainer, Ghadimi, Michael, Grützmann, Robert, Wittel, Uwe A, Jacobasch, Lutz, Uhl, Waldemar, Croner, Roland S., Bechstein, Wolf Otto, Neumann, Ulf Peter, Waldschmidt, Dirk, Boeck, Stefan Hubert, Moosmann, Nicolas, Reinacher-Schick, Anke C., Golcher, Henriette, Adler, Werner, Semrau, Sabine, Kallies, Annett, Hecht, Markus, Tannapfel, Andrea, Oettle, Helmut

“…4008 Background: Chemotherapy (CT) is the standard of care in nonresectable locally advanced pancreatic cancer. The CONKO-007 trial studied the role of…”
Get full text

Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? by Weiss, Lena, Heinemann, Volker, Fischer, Laura E., Gieseler, Frank, Hoehler, Thomas, Mayerle, Julia, Quietzsch, Detlef, Reinacher-Schick, Anke, Schenk, Michael, Seipelt, Gernot, Siveke, Jens T., Stahl, Michael, Vehling-Kaiser, Ursula, Waldschmidt, Dirk T., Dorman, Klara, Zhang, Danmei, Westphalen, C. Benedikt, von Bergwelt-Baildon, Michael, Boeck, Stefan, Haas, Michael

“…Purpose To analyze the 3-month life expectancy rate in pancreatic cancer (PC) patients treated within prospective trials from the German AIO study group…”
Get full text

Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence by Lyu, Su Ir, Fretter, Caroline, Simon, Adrian Georg, Spielmann, Sarah-Michele, Damanakis, Alexander I., Zhao, Yue, Bruns, Christiane J., Schmidt, Thomas, Popp, Felix C., Waldschmidt, Dirk, Quaas, Alexander, Knipper, Karl

“…•Zolbetuximab, a novel targeted therapy under investigation, targets Claudin 18.2.•We investigated the occurrence of Claudin 18.2 positivity in a real-world…”
Get full text

Sequence therapy in metastatic pancreatic cancer by Waidmann, Oliver, Pelzer, Uwe, Boeck, Stefan, Waldschmidt, Dirk-Thomas

“…Pancreatic cancer is one of the most lethal cancer diseases. For years, gemcitabine has been the standard of care and the only therapeutic option in patients…”
Get more information

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort by Finkelmeier, Fabian, Scheiner, Bernhard, Leyh, Catherine, Best, Jan, Fründt, Thorben Wilhelm, Czauderna, Carolin, Beutel, Alica, Bettinger, Dominik, Weiß, Johannes, Meischl, Tobias, Kütting, Fabian, Waldschmidt, Dirk-Thomas, Radu, Pompilia, Schultheiß, Michael, Peiffer, Kai-Henrik, Ettrich, Thomas J., Weinmann, Arndt, Wege, Henning, Venerito, Marino, Dufour, Jean-Francois, Lange, Christian M., Pinter, Matthias, Waidmann, Oliver

“…Background and Aims: The multikinase inhibitor cabozantinib has been approved for hepatocellular carcinoma (HCC) previously treated with sorafenib. We report…”
Get full text

Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort by Mitzlaff, Katharina, Kirstein, Martha M., Müller, Christian, Venerito, Marino, Olkus, Alexander, Dill, Michael T., Weinmann, Arndt, Kocheise, Lorenz, Busch, Alina, Schulze, Kornelius, Allo, Gabriel, Waldschmidt, Dirk‐Thomas, Barsch, Maryam, Bengsch, Bertram, Quante, Michael, Gonzalez‐Carmona, Maria A., Himmelsbach, Vera, Finkelmeier, Fabian, Kloeckner, Roman, Schirmacher, Peter, Marquardt, Jens U., Zimpel, Carolin

“…Background Combined Immuno‐chemotherapy consisting of gemcitabine, cisplatin and the programmed death‐ligand one inhibitor durvalumab (GCD) is the new standard…”
Get full text

Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma by Quaas, Alexander, Heydt, Carina, Waldschmidt, Dirk, Alakus, Hakan, Zander, Thomas, Goeser, Tobias, Kasper, Philipp, Bruns, Christiane, Brunn, Anna, Roth, Wilfried, Hartmann, Nils, Bunck, Anne, Schmidt, Matthias, Buettner, Reinhard, Merkelbach-Bruse, Sabine

“…Carcinomas of the small bowel are rare tumors usually with dismal prognosis. Most recently, some potentially treatable molecular alterations were described. We…”
Get full text

Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report by Reutter, Theresa, Fassunke, Jana, Püsken, Michael, Weber, Jan-Phillip, Binot, Elke, Eisert, Anna, Fischer, Rieke, Nogova, Lucia, Riedel, Richard, Schaufler, Diana, Scharpenseel, Heather, Scheffler, Matthias, Schulz, Holger, Waldschmidt, Dirk-Thomas, Zander, Thomas, Merkelbach-Bruse, Sabine, Schirmacher, Peter, Büttner, Reinhard, Wolf, Jürgen, Michels, Sebastian

Get more information

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine by Ceccon, Garry, Wollring, Michael, Brunn, Anna, Deckert, Martina, Waldschmidt, Dirk, Fink, Gereon R., Galldiks, Norbert

“…Leptomeningeal carcinomatosis is an extremely rare, but devastating complication in pancreatic cancer patients with a poor prognosis despite multimodal…”
Get full text

Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) by Weissinger, Florian, Auner, Holger W., Bertz, Hartmut, Buchheidt, Dieter, Cornely, Oliver A., Egerer, Gerlinde, Heinz, Werner, Karthaus, Meinolf, Kiehl, Michael, Krüger, William, Penack, Olaf, Reuter, Stefan, Ruhnke, Markus, Sandherr, Michael, Salwender, Hans-Jürgen, Ullmann, Andrew J., Waldschmidt, Dirk T., Wolf, Hans H.

“…More than 18,000 autolgous transplantation were performed in Europe in the year 2009. It as a routine procedure in experienced centres. Even if there is a low…”
Get full text

Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104 by Kruger, Stephan, Boeck, Stefan, Heinemann, Volker, Laubender, Ruediger P, Vehling-Kaiser, Ursula, Waldschmidt, Dirk, Kettner, Erika, Märten, Angela, Winkelmann, Cornelia, Klein, Stefan, Kojouharoff, Georgi, Gauler, Thomas C, Fischer von Weikersthal, Ludwig, Clemens, Michael R, Geissler, Michael, Greten, Tim F, Hegewisch-Becker, Susanna, Modest, Dominik P, Stintzing, Sebastian, Haas, Michael

“…Drug-induced skin toxicity may correlate with treatment efficacy in cancer patients receiving chemotherapy or biological agents. The correlation of the…”
Get more information

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial by Sinn, Marianne, Bahra, Marcus, Liersch, Torsten, Gellert, Klaus, Messmann, Helmut, Bechstein, Wolf, Waldschmidt, Dirk, Jacobasch, Lutz, Wilhelm, Martin, Rau, Bettina M, Grützmann, Robert, Weinmann, Arndt, Maschmeyer, Georg, Pelzer, Uwe, Stieler, Jens M, Striefler, Jana K, Ghadimi, Michael, Bischoff, Sven, Dörken, Bernd, Oettle, Helmut, Riess, Hanno

“…Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor…”
Get full text

Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma by Leuchte, Katharina, Staib, Elena, Thelen, Martin, Gödel, Philipp, Lechner, Axel, Zentis, Peter, Garcia-Marquez, Maria, Waldschmidt, Dirk, Datta, Rabi Raj, Wahba, Roger, Wybranski, Christian, Zander, Thomas, Quaas, Alexander, Drebber, Uta, Stippel, Dirk Ludger, Bruns, Christiane, von Bergwelt-Baildon, Michael, Wennhold, Kerstin, Schlößer, Hans Anton

“…Thermal ablative therapies are standard treatments for localized hepatocellular carcinoma (HCC). In addition to local tumor destruction, ablation leads to…”
Get full text

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study by Vogel, Arndt, Kasper, Stefan, Bitzer, Michael, Block, Andreas, Sinn, Marianne, Schulze-Bergkamen, Henning, Moehler, Markus, Pfarr, Nicole, Endris, Volker, Goeppert, Benjamin, Merx, Kirsten, Schnoy, Elisabeth, Siveke, Jens T., Michl, Patrick, Waldschmidt, Dirk, Kuhlmann, Jan, Geissler, Michael, Kahl, Christoph, Evenkamp, Ralph, Schmidt, Torben, Kuhlmann, Alexander, Weichert, Wilko, Kubicka, Stefan

“…Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent…”
Get full text

Open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC) by Gebauer, Florian, Schmidt, Thomas, Damanakis, Alexander, Quaas, Alexander, Cay, Duygu, Kehmann, Linde, Deuß, Burkhardt, Held, Swantje, Werner, Jens, Rehders, Alexander, Schineis, Christian, Reim, Daniel, Wittel, Uwe A, Werner, Jens, Glowka, Tim, Ronellenfitsch, Ulrich, Wiltberger, Georg, Mees, Sören T, Bruns, Christiane J., Waldschmidt, Dirk

“…TPS4193 Background: As of today, the recommendation for patients with adenocarcinoma of the pancreas and hepatic metastases is systemic chemotherapy alone…”
Get full text